The MVP Act is a top federal policy priority for AMCP. This important bipartisan bill will enhance Medicaid patient access to new, high-cost therapies by modernizing the framework for value-based purchasing arrangements.
On January 5, 2024, the Food and Drug Administration (FDA) issued a letter
authorizing the state of Florida’s Section 804 Importation Programs (SIP) proposal
(Authorization Letter).
Diabetes technology is the hardware, devices, and software that people with diabetes use to help manage their condition. Diabetes technology has expanded to include complex devices that both monitor blood sugar and deliver insulin. The American Diabetes Association now recommends use of continuous glucose monitoring (CGM) in individuals with both type 1 and type 2 diabetes. Rapid change in the diabetes technology landscape may lead to access barriers that can impact health plan programs, necessitating appropriate coverage policies.
